Navigation Links
Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea
Date:8/5/2010

MALVERN, Pa., Aug. 5 /PRNewswire/ -- Vicept Therapeutics, Inc., a privately held specialty biopharmaceutical company, announced positive results today from a pharmacodynamic and pharmacokinetic clinical trial of the Company's lead product V-101, a topical cream under investigation for the treatment of erythema in patients with rosacea.

The double-blinded, placebo-controlled, crossover clinical trial of 22 patients with rosacea was designed to evaluate the bioavailability of V-101 and provide preliminary evidence of efficacy as measured by improvement in moderate to severe erythema, the bright redness of the skin associated with rosacea.  V-101 had a side effect profile similar to placebo and V-101's active ingredient was not detectable in study participants' plasma, a strong indication of the product's overall tolerability and safety profile.  Additionally, the study results were positive for all endpoints, demonstrating a clinically and statistically significant improvement in treating the erythema associated with rosacea.

"This important study demonstrated that V-101 has a good safety profile and provides statistically significant evidence of effectiveness in treating the erythema of rosacea," said Dr. Neal Walker, president and chief executive officer of Vicept. "We look forward to advancing our clinical program into Phase II and continuing our efforts to develop this product for the 16 million people in the United States who live with this common, chronic skin condition every day."

"Rosacea is devastating to people who live with it and the primary complaint is erythema, the red sunburn appearance that accompanies the disease," said James Leyden, M.D., Professor E
'/>"/>

SOURCE Vicept Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO
2. United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 2010
3. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
4. Talecris Biotherapeutics to Report Second Quarter 2010 Financial Results
5. Talecris Biotherapeutics Announces Premerger HSR Filing
6. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
7. Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
8. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
9. United Therapeutics and Lees Pharmaceutical Sign Remodulin Distribution Agreement for China
10. Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts
11. Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015 The UPMC Center for Health ... in the Emerging Leaders in Biosecurity Initiative (ELBI). As ... the field of biosecurity, UPMC has selected 28 US ... array of backgrounds, including biological science, medicine, policy, the ... "With the vision and support of the Defense ...
(Date:3/4/2015)... CALGARY , March 4, 2015 /CNW/ ... that it has completed a collaborative research ... quantitative analytics.  Using Fast Collective Evolution Technology ... dataset including all measurements obtained from each ... Company,s Phase 2 clinical trials ASSERT, SUSTAIN ...
(Date:3/4/2015)... , March 4, 2015 Vegalab announced ... in August of last year. As part of the ... Bon Koo continuing his role as CEO for ... of Vegalab S.A., will work alongside Koo and oversee ... - http://photos.prnewswire.com/prnh/20150303/179218 Koo founded ...
(Date:3/3/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: ... diagnostics that target the underlying mechanisms of cancer, today ... ended December 31, 2014. Effective July 17, ... May 31 to December 31. As a result of ... for the quarter and the seven months ended December ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... 12 TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) today ... 2008. For the three-month period, the Company posted,revenue of ... Cash and cash,equivalents totaled $14.3 million at September 30, ... productive as we further,our transition to a development-only company," ...
... CONSHOHOCKEN, Pa., Nov. 12 GEL Interactive,Technologies, a ... Product Director, will be a featured speaker at ... Forum on Defining Appropriate,and Effective Interactions with Thought ... Annual Forum provides a platform for attendees to ...
... Inc.,(Nasdaq: BNVI ) announced today the appointment of ... Weiss is a cardiologist with,expertise in clotting and coagulation ... Institute and the Division of Cardiology at,the University of ... to have Ethan on the scientific advisory board as,we ...
Cached Biology Technology:TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 2TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 3TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 4TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 5TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 6TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments 7Cadient Group's GEL Interactive Technologies to Present and Exhibit at CBI's 5th Annual Forum 2Ethan Weiss, M.D., Joins Bionovo's Scientific Advisory Board 2Ethan Weiss, M.D., Joins Bionovo's Scientific Advisory Board 3
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , ... cancer, today announced that Murali Prahalad , Ph.D., president ... Medicine World Conference (PMWC) 2015: Silicon Valley, which is ... Mountain View, Calif. on January 26-28, 2015. ... Come of Age as Biomarkers." Last year, Epic Sciences was ...
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... - A Global Market Overview" report to their offering. ... is to ensure that an individual is who she/he is ... make use of a person,s unique physical characteristics, such as ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... this weeks PLoS Medicine, researchers have found that more ... infectious eye disease trachoma. Six million people most ... the developing world are blind because of the ... that multiple strains of the Chlamydiceae family of bacteria ...
... Hydrogen peroxide, the same mild acid that many people use ... also produced by the body to keep cells healthy. Now, ... how part of this complex process works. Reporting ... by W. Todd Lowther, Ph.D., developed a three-dimensional snapshot of ...
... coalition of 17 organizations, including the National Academy ... the National Science Teachers Association, is calling on ... the promotion of science education, including evolution. According ... issue of The FASEB Journal, the introduction of ...
Cached Biology News:Multiple species of bacteria may cause trachoma: Implications for treatment 2Research explores role of hydrogen peroxide in cell health 2Evolution education is a 'must' says coalition of scientific and teaching organizations 2
... Satellite Thermal Cycler (MBS) is ... for medium to high throughput ... the latest in satellite block ... PC control, resulting in a ...
...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
CQCS kit for etra KR 4i , (other units)....
Biology Products: